136 related articles for article (PubMed ID: 32894808)
1. Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.
Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Takeda H; Takai A; Takahashi K; Seno H
J Hepatobiliary Pancreat Sci; 2020 Dec; 27(12):913-921. PubMed ID: 32894808
[TBL] [Abstract][Full Text] [Related]
2. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma.
Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Nakamura F; Takeda H; Takai A; Takahashi K; Taura K; Seno H
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877859
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Nutrition Index as an Indicator of Therapeutic Response to Lenvatinib Therapy in Hepatocellular Carcinoma.
Shibano M; Takahashi K; Takahashi M; Uchida-Kobayashi S; Kawada N; Nakamura Y; Otori T; Nagayama K
Anticancer Res; 2022 Dec; 42(12):6019-6026. PubMed ID: 36456132
[TBL] [Abstract][Full Text] [Related]
4. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma.
Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Takeda H; Takai A; Takahashi K; Taura K; Seno H
J Hepatobiliary Pancreat Sci; 2021 Jun; 28(6):498-507. PubMed ID: 33787071
[TBL] [Abstract][Full Text] [Related]
5. Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma.
Shimose S; Koya S; Kawaguchi T; Hirota K; Yoshio S; Niizeki T; Matsuse H; Torimura T
Clin Mol Hepatol; 2021 Oct; 27(4):616-619. PubMed ID: 34517441
[No Abstract] [Full Text] [Related]
6. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
7. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T
J Gastroenterol Hepatol; 2015 Sep; 30(9):1412-9. PubMed ID: 25799910
[TBL] [Abstract][Full Text] [Related]
8. Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma.
Okuno M; Hatano E; Tada M; Nishimura T; Okamoto T; Sueoka H; Iida K; Nakamura I; Iijima H; Hirono S
Anticancer Res; 2024 Apr; 44(4):1727-1737. PubMed ID: 38537993
[TBL] [Abstract][Full Text] [Related]
9. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
11. Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study.
Kinoshita A; Hagiwara N; Osawa A; Akasu T; Matsumoto Y; Ueda K; Saeki C; Oikawa T; Koike K; Saruta M
J Oncol Pharm Pract; 2023 Apr; 29(3):626-636. PubMed ID: 35112972
[TBL] [Abstract][Full Text] [Related]
12. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
13. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
15. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.
Noda S; Iida H; Fujimoto T; Wakasugi Y; Yabuta N; Sudou M; Hira D; Tani M; Andoh A; Morita SY; Terada T
Cancer Chemother Pharmacol; 2021 Aug; 88(2):281-288. PubMed ID: 33928425
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(10):611-621. PubMed ID: 34139691
[TBL] [Abstract][Full Text] [Related]
17. The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma.
Kinoshita A; Hagiwara N; Osawa A; Akasu T; Matsumoto Y; Ueda K; Saeki C; Oikawa T; Koike K; Saruta M
In Vivo; 2022; 36(2):865-873. PubMed ID: 35241544
[TBL] [Abstract][Full Text] [Related]
18. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
19. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
[TBL] [Abstract][Full Text] [Related]
20. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
